Abstract IA15: “Next-gen” genomics-based clinical trials

摘要: Next generation sequencing (NGS) technologies have gained increasing clinical applications as a strategy to screen and identify patients for genomic based trials in oncology. Molecular characterization programs using NGS been established many cancer centers worldwide, including some that comprise part of nation-based efforts. With growing number whose tumors undergone molecular profiling, there is an urgent need justify these activities translate findings into clinically relevant outcome. profiling offers information beyond the histopathological classification tumors, subdividing them smaller subsets ranging from those harboring common recurrent aberrations others with rare variants uncertain significance. The current era populated by “umbrella” “basket” which allocate druggable signatures specific genotype-drug matched groups remain histology-based (“umbrella” trials) or are histology-agnostic (“basket” trials). pros cons trial designs, their ability bring value precision medicine bear, will be discussed. Looking present framework, it unlikely genomics sufficient standalone fully characterize complex landscape cancer. “Next-gen” target dynamic status take consideration intratumoral heterogeneity design. extension algorithms include transcriptomics epigenetics attractive encompass other alterations can lead unchecked tumor growth. A systems biology approach should considered understand signaling pathway interactions decipher mechanisms oncogenic dependence, especially lack readily actionable profiles. There close between genome immunome such may inform selection most likely benefit immune-based therapies. must capable interrogating multifaceted manner order achieve substantial incremental benefits therapeutic Citation Format: Lillian L. Siu. genomics-based trials. [abstract]. In: Proceedings AACR Precision Medicine Series: Integrating Clinical Genomics Cancer Therapy; Jun 13-16, 2015; Salt Lake City, UT. Philadelphia (PA): AACR; Clin Res 2016;22(1_Suppl):Abstract nr IA15.